tiprankstipranks
Trending News
More News >

Avidity Biosciences: Japan’s MHLW grants ODD to delpacibart etedesiran

Avidity Biosciences (RNA) announced that the Japan Ministry of Health, Labour and Welfare has granted Orphan Drug designation to delpacibart etedesiran for the treatment of myotonic dystrophy type 1, an investigational treatment designed to address the root cause of DM1, an underrecognized, progressive and often fatal neuromuscular disease with no approved therapies. Del-desiran is the first investigational treatment for DM1 to receive Orphan Drug designation in Japan. Del-desiran has also received Breakthrough Therapy, Orphan Drug and Fast Track designations by the U.S. FDA and Orphan designation by the European Medicines Agency.

Confident Investing Starts Here:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.

Report an Issue